Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Cellectar Biosciences Inc Market Cap
The Cellectar Biosciences Inc (CLRB) share price is expected to increase by 491.55% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered CLRB. Price targets range from $4 at the low end to $25 at the high end. The current analyst consensus for CLRB is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned CLRB 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Cellectar Biosciences Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CLRB. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CLRB.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jeff Jones Oppenheimer | Outperform | $12 | Reiterates | Mar 28, 2024 |
| Jonathan Aschoff Roth MKM | Buy | $28 | Maintains | Mar 28, 2024 |
| Jonathan Aschoff Roth MKM | Buy | $20 | Reiterates | Mar 4, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $4 | Maintains | Nov 4, 2022 |
| Jeff Jones Oppenheimer | Outperform | $5.5 | Assumes | Jul 18, 2022 |
Roth Capital | Buy | Initiates | Nov 25, 2020 | |
Ladenburg Thalmann | Buy | Initiates | Nov 25, 2020 | |
H.C. Wainwright | Buy | Initiates | Nov 25, 2020 | |
Brookline Capital | Buy | Initiates | Nov 25, 2020 | |
Maxim Group | Buy | Initiates | Nov 25, 2020 | |
Oppenheimer | Outperform | Initiates | Nov 25, 2020 | |
Oppenheimer | Outperform | Initiates | Jul 1, 2020 | |
Maxim Group | Buy | Initiates | Jun 23, 2020 | |
Roth Capital | Buy | Initiates | Sep 13, 2019 | |
Brookline Capital | Buy | Initiates | Jul 30, 2019 | |
H.C. Wainwright | Buy | Initiates | May 2, 2019 | |
Ladenburg Thalmann | Buy | Initiates | Dec 21, 2016 |
When did it IPO
N/A
Staff Count
20
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. James V. Caruso
Market Cap
$78.9M
In 2023, CLRB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CLRB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - CLRB announces two presentations featuring its Iopofosine I 131 at the 12th IWWM, in Prague. Jorge Castillo will be the presenter.
Mon, 26 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Jorge Castillo, M.D. to Present Iopofosine I 131 Activity in Bing-Neel Syndrome Andrei Shustov, M.D.
Fri, 23 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FLORHAM PARK, N.J., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the Company had received an expected delinquency notification letter (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) on August 20, 2024. The Notice indicated that the Company is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Second Quarter 10-Q”), by the applicable due date.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Jim Caruso – President and Chief Executive Officer Andrei Shustov – Senior Vice President-Medical Jarrod Longcor – Chief Operating Officer Shane Lea – Chief Commercial Officer Chad Kolean – Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Jeff Jones – Oppenheimer Ted Tenthoff – Piper Sandler Operator Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call. Today's call is being recorded.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
